 |
Owen Gordon
Director, Finance and Corporate Development
Owen Gordon is a Chartered Accountant with 15 years of experience within
the life science industry. Prior to joining Axela in June of 2003, he was
Director of Business Development at a venture-backed software company focused
on managing unstructured data in drug discovery. In addition to being actively
involved in the company's successful sale to Open Text Corporation, he
was instrumental in the formation of Open Text's first vertical industry-focused
SBU for life sciences. Prior to this, he was responsible for Business Development
at Eli Lilly Canada where he engaged in transactions including negotiation
of in-licensing and outlicensing deals plus working on the company's successful
ultrageneric strategy for Prozac. Prior to this Mr. Gordon worked in financial
capacities of increasing levels of responsibility at Bayer (Miles) Canada
and Amgen Canada respectively.
|
